KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.

Naoto Takahashi, Yoshikane Kikushige, Hirohisa Nakamae, Tatsunori Goto, Akihiro Tomita, Michiko Ichii, Satoshi Ito, Takanori Teshima, Keita Kirito, Takayuki Ikezoe, Kaoru Hatano, Hirokazu Tanaka, Nobuhiro Hiramoto, Ryohei Osako, Makoto Aoki, Kamel Malek, Yasunori Ueda

Int J Hematol 122(5) 647-659

PMID40418277
PMCIDPMC12572060
DOI10.1007/s12185-025-04014-z
发表日期2025-05-26
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

INTRODUCTION: The phase III ASC4FIRST study (NCT04971226) demonstrated superior efficacy and favorable safety and tolerability for asciminib against investigator-selected tyrosine kinase inhibitors (IS-TKI) in newly diagnosed chronic myeloid leukemia (CML). Results of a subgroup analysis in Japanese patients are presented here. METHODS: Adult patients were randomized 1:1 to asciminib or IS-TKI following stratification by European Treatment and Outcome Study long-term survival risk score and prerandomization-selected TKI (imatinib and second-generation [2G] TKI strata). At week 48, major molecular response (MMR) rate in all patients and imatinib stratum (primary endpoints) were assessed along with MR4.0, MR4.5, and safety (cutoff: November 28, 2023). RESULTS: In Japanese patients (asciminib, n = 21; IS-TKI, n = 17 [imatinib/2G TKI, n = 8/9]), the MMR rate was higher with asciminib (81.0%) than IS-TKI (47.1%), and versus imatinib (asciminib: 100%; imatinib: 25.0% [imatinib stratum]). More patients on asciminib than IS-TKI achieved MR4.0 (57.1% vs. 11.8%) and MR4.5 (28.6% vs. 5.9%). Fewer grade ≥ 3 adverse events (AEs; 42.9%, 50.0%, and 55.6%) and AEs leading to treatment discontinuation (0%, 37.5%, and 11.1%) occurred with asciminib than imatinib or 2G TKI. CONCLUSION: Outcomes in Japanese patients were consistent with the ASC4FIRST overall population. Asciminib may be a therapy of choice for Japanese patients with CML.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 6

Fig. 6 Cumulative incidence of A MMR, B MR 4.0 , and C MR 4.5 in patients receiving asciminib or IS-TKI

A

MMR

Fig. 6 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

MR4.0

Fig. 6 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:short span曲线 2:very low support
查看结果
C

MR4.5

Fig. 6 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:very low support曲线 2:extreme jump
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 MMR at week 48 in the asciminib and IS-TKI arms in A all patients, B imatinib stratum, and C 2G TKI stratum. 2G second generation, CI confidence interval, IS-TKI investigator-selected tyrosine kinase inhibitor, MMR major molecular response, TKI tyrosine kinase inhibitor, n represents patient numbers in each arm. Common risk difference and 95% CI between the arms shown for full analysis group, imatinib and 2G TKI strata
非 KM Figure
Fig. 2Fig. 2 EMR at week 12 in the asciminib and IS-TKI arms in A all patients, B imatinib stratum, and C 2G TKI stratum. 2G second generation, EMR early molecular response, IS-TKI investigator-selected tyrosine kinase inhibitor, TKI tyrosine kinase inhibitor; n represents patient numbers in the full analysis set for each arm. EMR is BCR::ABL1 IS ≤ 10% at week 12
非 KM Figure
Fig. 3Fig. 3 BCR::ABL1 IS ≤ 1% at week 48 in the asciminib and IS-TKI arms in A all patients, B imatinib stratum, and C 2G TKI stratum. 2G second generation, CI confidence interval, IS-TKI investigator-selected tyrosine kinase inhibitor, TKI tyrosine kinase inhibitor, n represents patient numbers in the full analysis set for each arm. a Common risk difference (95% CI) between the arms
非 KM Figure
Fig. 4Fig. 4 MR 4.0 at week 48 in the asciminib and IS-TKI arms in A all patients, B imatinib stratum, and C 2G TKI stratum. 2G second generation, CI confidence interval, IS-TKI investigator-selected tyrosine kinase inhibitor, MR molecular response, TKI tyrosine kinase inhibitor, n represents patient numbers in the full analysis set for each arm. a Common risk difference (95% CI) between the arms
非 KM Figure
Fig. 5Fig. 5 MR 4.5 at week 48 in the asciminib and IS-TKI arms in A all patients, B imatinib stratum, and C 2G TKI stratum. 2G second generation, CI confidence interval, IS-TKI investigator-selected tyrosine kinase inhibitor, MR molecular response, TKI tyrosine kinase inhibitor, n represents patient numbers in the full analysis set for each arm. a Common risk difference (95% CI) between the arms
非 KM Figure